Real‐World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort
Authors' conclusion
Tirzepatide was associated with substantial weight loss and significant patient-reported benefits including mood and mobility improvement. Treatment continuity was a correlate of effectiveness, and maximal dose escalation was often unnecessary.
Study context
- Population
- Adults initiating tirzepatide for obesity via a UK digital prescribing service, March 2024–July 2025; 80.3% female, mean BMI 36.1 kg/m² (SD 5.8)
- Participants
- 630,545 eligible patients
- Outcome
- Percentage weight change
- Follow-up
- 6 months
Methodological detailsreal-world, digital prescribing service
- Real-world
- Digital prescribing service
Main finding
As reported in the abstract
Mean % weight change
Recorded weights
−13.5
mean · 95% CI −13.56–-13.51 · %
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Mean % weight change · 12 months | Recorded weights mean −17.4 (95% CI −17.5–-17.3) % |
- Mean % weight change: n = 58 434 with recorded weights
Weight-loss thresholds · 6 months
- Achieved ≥5% weight loss
- 89.9%
- Achieved ≥10% weight loss
- 72.1%
Ordering cadence and dose
- More regular ordering cadence associated with greater weight loss; clinically meaningful outcomes frequently achieved without escalation beyond intermediate doses
Treatment persistence by deprivation
- More prescription orders in less vs most deprived areas
- 26.1%
Patient-reported outcomes (6-month survey)
- Improved mobility
- 46.7%
- Improved mood
- 45.9%
- Reduced alcohol consumption
- 26.7%
Original publication
Real‐World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort. Diabetes Obes Metab. Published 6 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →